Skip to main content
Top
Published in: Investigational New Drugs 4/2017

01-08-2017 | Erratum

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

Authors: Valentine Heidelberger, François Goldwasser, Nora Kramkimel, Anne Jouinot, Olivier Huillard, Pascaline Boudou-Rouquette, Johan Chanal, Jennifer Arrondeau, Nathalie Franck, Jérôme Alexandre, Benoît Blanchet, Karen Leroy, Marie-Françoise Avril, Nicolas Dupin, Sélim Aractingi

Published in: Investigational New Drugs | Issue 4/2017

Login to get access

Excerpt

Erratum to: Invest New Drugs 2017
Metadata
Title
Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
Authors
Valentine Heidelberger
François Goldwasser
Nora Kramkimel
Anne Jouinot
Olivier Huillard
Pascaline Boudou-Rouquette
Johan Chanal
Jennifer Arrondeau
Nathalie Franck
Jérôme Alexandre
Benoît Blanchet
Karen Leroy
Marie-Françoise Avril
Nicolas Dupin
Sélim Aractingi
Publication date
01-08-2017
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0475-7

Other articles of this Issue 4/2017

Investigational New Drugs 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine